Will This Biotech Stock Join the $1,000 Human Genome Club in Early 2019?

Pacific Biosciences thinks platform upgrades will cut its Sequel machines' DNA sequencing costs 92% by 2019, opening a $2.5 billion market opportunity in 2022.